Beyond first-line therapy: efficacy and safety outcomes of continuing immunotherapy in extensive stage small cell lung cancer after PD-L1 inhibitor progression

Beyond first-line therapy: efficacy and safety outcomes of continuing immunotherapy in extensive stage small cell lung cancer after PD-L1 inhibitor progression

Objective: To evaluate the efficacy and safety of the continuing immunotherapy as subsequent therapy in extensive-stage small cell lung cancer (ES-SCLC) patients who have progressed after initial immunotherapy. Methods: A retrospective analysis was conducted on patients with ES-SCLC who experienced...

Full description

Saved in:
Bibliographic Details
Main Authors: Jianfeng Peng, Xueying Zhai, Xiaomei Liu, Zhaoqin Huang, Yimeng Wang, Peizhu Wu, Ran Gao, Xiangjiao Meng
Format: Article
Language:English
Published: Elsevier 2025-02-01
Series:Translational Oncology
Subjects:
extensive-stage small cell lung cancer
immunotherapy
immunotherapy beyond progression
second-line treatment
survival
Online Access:http://www.sciencedirect.com/science/article/pii/S1936523324003759
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items